Kevzara

RSS

sarilumab

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Kevzara. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kevzara.

For practical information about using Kevzara, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 30/11/2022

Authorisation details

Product details
Name
Kevzara
Agency product number
EMEA/H/C/004254
Active substance
sarilumab
International non-proprietary name (INN) or common name
sarilumab
Therapeutic area (MeSH)
Arthritis, Rheumatoid
Anatomical therapeutic chemical (ATC) code
L04AC14
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Sanofi Winthrop Industrie
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
23/06/2017
Contact address

82 Avenue Raspail
94250 Gentilly
France

Product information

18/11/2022 Kevzara - EMEA/H/C/004254 - T/0034

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Kevzara in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Kevzara can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.

Assessment history

Related content

How useful was this page?

Add your rating
Average
2 ratings
2 ratings
3 ratings